Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Health Care · CIK 0002046386
$35.31
-0.42% · delayed ~15 min
Last price from Oct 21, 2026
$28.60B market value
From Medline Inc.'s FY2025 10-K, filed Feb 25, 2026 · read the filing
Medline makes medical devices and equipment. It took in $28.43B last year, which makes it a large company. Of every dollar it sells, about 4 cents is left as profit.
The financial picture is led by accounting, with profitability and growth worth watching, while debt remain weak.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by 5 insiders, not under a pre-arranged plan.
$1.15B sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From Medline Inc.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Cash
$199.0M → $1.94B
Long-term debt
$16.42B → $12.48B
Capital spending
$354.0M → $447.0M
Revenue
$25.51B → $28.43B
Measured against FY2024, from the 10-K filed Feb 25, 2026
Improved: +874.4%
$199.0M to $1.94BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: -24.0%
$16.42B to $12.48BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
How the latest move compares (quote delayed ~15 min), and what was published around it
MDLN fell 0.42% on the latest quote. The average Health Care company tracked here moved +1.62%, and the S&P 500 −1.04%. That is 2.0 points below its sector and 0.6 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 11% a year for the next 10 years. Over the last 2 years it shrank by about 4% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 4 cents of every dollar of sales as profit, earning $1.16B last year.
Slowly. Sales grew 11.5% last year.
Yes. Clearing its debt would take roughly 6.1 years of cash flow. For every $1 it owes, it owns $2.00 in assets.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $1.16B and generated $1.74B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 25, 2026Filing for FY2025 | FY202410-K · Feb 25, 2026Filing for FY2024 | FY202310-K · Feb 25, 2026Filing for FY2023 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|
| RevenueWhat is this? | $28.43B | $25.51B | $23.23B | +11.5% |
| Cost of revenue | $20.91B | $18.53B | $17.35B | +12.9% |
| Gross profit | $7.52B | $6.98B | $5.88B | +7.8% |
| Gross marginGross profit ÷ revenueWhat is this? | 26.4% | 27.3% | 25.3% | −0.9 pts |
| Selling, general and administrative | $4.52B | $4.11B | $3.87B | +10.1% |
| Operating income | $2.21B | $2.15B | $1.25B | +3.1% |
| Operating marginOperating income ÷ revenueWhat is this? | 7.8% | 8.4% | 5.4% | −0.6 pts |
| Interest expense | $945.0M | $1.14B | $1.21B | −17.4% |
| Income before tax | $1.25B | $1.25B | $264.0M | +0.2% |
| Net income | $1.16B | $1.16B | $234.0M | −0.3% |
| Net marginNet income ÷ revenueWhat is this? | 4.1% | 4.6% | 1.0% | −0.5 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $1.43 | — | — | — |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| MDLNMedline Inc. · this page | 6.0/10 | 6/8 | 11.5% | 4.1% |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Sold on the open market — 7,816,987 shares at $35.15 ($274.8M)
Holds 69,408,506 shares after this filing.
Sold on the open market — 2,570,999 shares at $35.35 ($90.9M)
Holds 20,231,483 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Made a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join
Read the filingWrite down why you are following Medline Inc., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 128 subsidiaries named in its 10-K, incorporated across 50 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from MDLN's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 25, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 8 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 6.0 | 6/8 | 10-K, filed Feb 25, 2026 |
| FY2024 | 4.7 | 4/4 | 10-K, filed Feb 25, 2026 |
| FY2023 | 6.0 | 2/2 | 10-K, filed Feb 25, 2026 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
6 of 8 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. One could not be evaluated and is excluded from the total rather than counted as a failure.
2.08
In the grey zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.39
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Changed: +26.3%
$354.0M to $447.0MSignificant
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Improved: +11.5%
$25.51B to $28.43BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +7.8%
$6.98B to $7.52BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: -8.3%
$1.42B to $1.30BNotable
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Q2 FY2026 against Q2 FY2026, from the 10-Q filed Aug 5, 2026 — read it.
Deteriorated: -57.8%
$329.0M to $139.0MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +298.5%
$584.0M to $2.33BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +16.3%
$1.91B to $2.21BSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: -38.5%
$642.0M to $395.0MSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: −4.2 pts
9.3% to 5.1%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +11.6%
$6.89B to $7.68BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +1.2 pts
27.7% to 28.8%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: −3.0 pts
4.8% to 1.8%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 5, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: -41.8%
$239.0M to $139.0MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: -44.4%
$0.29 to $0.16Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +20.3%
$1.84B to $2.21BSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +3.8 pts
25.0% to 28.8%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: -6.4%
$422.0M to $395.0MNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: −1.4 pts
3.3% to 1.8%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: +4.6%
819.1M to 856.7MNotable
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
5 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 9% and 13%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 34 analysts covering this company, as of . Their views, not this site's.
Of 34 analysts publishing on this company, 12 say strong buy, 15 say buy and 7 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 6.5% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 27.9x — investors pay $27.9 for each $1 of trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 24.68x |
| 1.79x |
| ALGNALIGN TECHNOLOGY INC | 8.7/10 | 6/8 | 0.9% | 10.2% | 27.04x | 0.54x |
|---|
| Median of peers | 8.7/10 | — | 0.9% | 10.2% | 27.04x | 0.54x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Sold on the open market — 7,146,941 shares at $34.33 ($245.4M)
Holds 84,408,506 shares after this filing.
Sold on the open market — 1,688,690 shares at $35.78 ($60.4M)
Holds 18,542,793 shares after this filing.
Sold on the open market — 2,088,987 shares at $35.05 ($73.2M)
Holds 16,453,806 shares after this filing.
Sold on the open market — 7,183,013 shares at $35.05 ($251.8M)
Holds 77,225,493 shares after this filing.
Sold on the open market — 1,500,000 shares at $35.80 ($53.7M)
Holds 22,902,482 shares after this filing.
Sold on the open market — 100,000 shares at $35.80 ($3.6M)
Holds 22,802,482 shares after this filing.
Sold on the open market — 590,284 shares at $35.58 ($21.0M)
Holds 24,402,482 shares after this filing.
Sold on the open market — 1,710,907 shares at $35.46 ($60.7M)
Holds 25,530,471 shares after this filing.
Sold on the open market — 265,711 shares at $36.48 ($9.7M)
Holds 25,264,760 shares after this filing.
Sold on the open market — 271,994 shares at $35.33 ($9.6M)
Holds 24,992,766 shares after this filing.
Converted a derivative security — 500,000 shares
Holds 787,648 shares after this filing.
Reported another kind of transaction — 500,000 shares
Holds 233,520,656 shares after this filing.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Quarterly report for Q2 FY2026
Revenue +11.6% · Operating margin −4.2 pts · Profit -57.8% — against Q2 FY2026
Published results
Read the filingHad a director or senior officer leave or join
Read the filingHeld a shareholder vote
Read the filingSigned a material agreement · Took on a direct financial obligation · Reported another event
Read the filingS-1MEF
Read the filingRegistration statement for an offering of securities
Read the filingQuarterly report for Q1 FY2026
Revenue +10.7% · Operating margin −2.9 pts · Free cash flow -45.9% — against Q1 FY2026
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingRegistration statement for an offering of securities
Read the filingAnnual report for FY2025
Revenue +11.5% · Cash +874.4% · Long-term debt -24.0% — against FY2024
Read the filingPublished results
Read the filingSigned a material agreement · Changed the rights attached to its shares · Had a director or senior officer leave or join · Amended its charter or changed its financial year · Reported another event
Read the filingS-1MEF
Read the filingRegistration statement for an offering of securities
Read the filingRegistration statement for an offering of securities
Read the filingRegistration statement for an offering of securities
Read the filingThe first 40 of 128. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-25. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Mizuho Maintains Outperform on Medline, Lowers Price Target to $45
Benzinga ·
Medline Announces Removal And Market Exit Of All Medline Brand Beds, Estimates Costs Of Up To $220M, Says No Material Impact On FY2026 Guidance
Benzinga ·
What Capital Group Core Equity ETF (CGUS) Bought: Medline Leads on Thursday
Yahoo ·
Medline Inc.: Beware The Private Equity Overhang
SeekingAlpha ·
Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
Yahoo ·
Reported October 12, 2026: Medline Signs Prime Vendor Agreement With South Carolina Pediatric Alliance To Support 10 Pediatric Care Locations
Benzinga ·
Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
Yahoo ·
Barclays Maintains Overweight on Medline, Lowers Price Target to $43
Benzinga ·
Medline to report third quarter 2026 results on November 4, 2026
Yahoo ·
UBS Maintains Buy on Medline, Lowers Price Target to $43
Benzinga ·
Astellas lists 431K sf Northbrook HQ in possible sale-leaseback play
Yahoo ·
Medical Textile Market Global Report 2026: A $39.53 Billion Revenue Surge to $64.28 Billion by 2030 at 26.9% CAGR, Benchmark 3M, Medline Industries, Cardinal Health, and DuPont to Secure Market Share
Yahoo ·
Primary sources and further research